Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 625-629

  Fotiou, Stelios ^a,c   Tserkezoglou, Aliki ^a   Hadjieleftheriou, George ^a   Apostolikas, Nikiforos ^b   Karydas, Irene ^b   Stravolemos, Kouris ^b  

^a G Papanicolaou Research Center for Oncology   (Greece)

^b Cancer Hospital   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Metrorrhagia; Tamoxifen; Uterine lesions

Indexed keywords

TAMOXIFEN;

ADENOMYOSIS; ADULT; AGED; ARTICLE; BREAST CANCER; CURETTAGE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; HYSTERECTOMY; LAPAROTOMY; LEIOMYOMA; MAJOR CLINICAL STUDY; OVARY TUMOR; POLYP; PRIORITY JOURNAL; UTERINE CERVIX; UTERUS BLEEDING;

ADENOCARCINOMA; ADULT; AGED; BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; POLYPS; RETROSPECTIVE STUDIES; TAMOXIFEN; UTERINE DISEASES; UTERINE HEMORRHAGE;

EID: 0031946885     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Riberio G and Swindell R: The Christie Hospital adjuvant tamoxifen trial:status at ten years. Br J Cancer 57: 601-603, 1988.
2. Baum M: Controlled trial of tamoxifen as single agent in the management of early breast cancer: Analysis at six years by Nolvadex Adjuvant Trial Organization. Cancer 1: 836-839, 1985.
3. Wolf DM and Jordan CV: Gynecologic complications associated with long term tamoxifen for breast cancer. A review. Gynecol Oncolol 45: 118-128, 1992.
4. Mauvais J, Kuttenn F and Gompel A: Estradiol / Progesterone interaction in normal and pathologic breast cells. Ann NY Acad Sei 464: 15 2-167, 1986.
5. Lees JA, Fawell SE and Parker MD: Identification of constitutive and steroid dependent transactivation domains in the mouse oestrogen receptor. J Steroid Biochem 34: 33-39, 1989.
6. Weiss OJ and Gurpide E: Non-genomic effects of estrogens and antiestrogens. J Steroid Biochem 31: 671-676, 1988.
7. Anderson M, Storm HH and Mouridsen TH: Incidence of new primary cancers after adjuvant therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013-1017, 1991.
8. Atlante G, Pozzi M, Vincenzoni C and Vocaturo E: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378-380, 1990.
9. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silversward C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 2: 2641-2643, 1989.
10. Hardell L: Tamoxifen as risk factor for carcinoma of the corpus uteri. Lancet 2: 563, 1988.
11. Hardell L: Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet 2: 1432, 1988.
12. Killackey MA, Hakes TB and Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69: 237-238, 1985.
13. Malfetano JH: Tamoxifen associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39: 82-84, 1990.
14. Mathew A, Chabon AB, Kabakow B, Drucker M and Hirschman RJ: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 90: 207-208, 1990.
15. Cohen I, Rosen DJ, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D and Beyth Y: Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 100: 567-570, 1993.
16. Cohen I, Rosen DJ, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D and Beyth Y: Comparison between tamoxifen treated and nontreated asymptomatic postmenopausal breast cancer patients. Gynecol Oncol 52: 185-190, 1994.
17. Spinelli G, Bardazzi N, Citernezi A, Fontanarosa M and Curill P: Endometrial carcinoma in tamoxifen treated breast cancer patients. J Chemother 3: 276-280, 1991.
18. Seoud MA, Johnson J and Weed JC: Gynecologic tumors in tamoxifen treated women with breast cancer. Obstet Gynecol 82: 165-169, 1993.
19. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham L, Cronin WM and other NSABP contributors: Endometrial cancer in tamoxifen treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP). JNCI 86: 527-537, 1994.
20. Van Leeuwen FE, Beuraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, Van den Belt-Dusenbont AW and Van Tinteren H: Risk of endometrial cancer after treatment of breast cancer. Lancet 343: 448-452, 1994.
21. Robinson DC, Bloss JD and Schiano MA: A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 59: 186-190, 1995.
22. Cohen I, Beyth Y, Tepper R, Figer A, Shapira J, Cordoba M, Yigael D and Altaras MM: Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: A new entiry? Gynecol Oncol 58: 86-91, 1995.
23. Cohen I, Beyth Y, Tepper R, Shapira J, Zadel Y, Figer A, Cordoba M, Yigael D and Altaras M: Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol 60: 54-58, 1996.
24. Gibson LE, Barakat RR, Venkatzaman ES et al: Endometrial pathology at dilatation and curettage in breast cancer patients: Comparison of tamoxifen users and non users. The Cancer Journal 2: 35-38, 1996.
25. Rutqvist LE, Johansson H, Signomklao T et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645-651, 1995.
26. Peters Engl C, Medl M, Danmayr E, Miran M, Alth G, Leodolter S: Endometrial cancer after tamoxifen treatment: A descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer. Anticancer Res 16: 3241-3246, 1996.
27. Gottardis MM, Robinson SP, Satyaswarroop PG and Jordan VC: Contrasting action of tamoxifen on endometrial and breast tumor growth in athymic mouse. Cancer Res 48: 812-815, 1988.
28. Cook GB: A comparison of single and multiple primary cancer. Cancer 19: 959, 1966.
29. Hoover R, Everson R, Fraumeri JF and Jr. Myers MH: Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet 1: 885-888, 1976.
30. MacMahon B and Austin JH: Association of carcinoma of the breast and corpus uteri. Cancer 23: 275, 1989.
31. Horwitz RI and Feinstein AR: Esrogens and endometrial cancer. Responses to arguments and current status of an epidemiologic controversy. Am J Med 81: 503-507, 1986.
32. Adami HO, Kruesmo KB, Bergkvist L, Person I and Petterson B: On the age dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer 55: 77-80, 1987.
33. Lahti E, Vuopala S, Kauppila A, Blanco J, Ruokonen A and Laatikainen T: Maturation of vaginal and endometrial epithelium in post menopausal breast cancer patients receiving long term tamoxifen. Gynecol Oncol 55: 410-414, 1994.
34. Neven P, De Muylder Y, Van Belle Y, Vanderick G and De Muylder E: Tamoxifen and the uterus and endometrium. Lancet 2: 375, 1988.
35. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS and Livolsi VA: Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 79: 111-116, 1992.
36. Cross SS and Ismail SM: Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report. Br J Obstet Gynaecol 97: 190-192, 1990.
37. Nuovo MA, Nuovo EJ, McCaffrey RM, Levine RU, Barron B and Wrinkler B: Endometrial polyps in postmenopausal patients receiving tamoxifen treatment. Int J Gynecol Pathol 8: 125-131, 1989.
38. Lahti E, Blanco G, Kauppila A, Apaja-Sakkinen M, Taskinen PJ and Laatikainen T: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81: 660-663, 1993.
39. Barakat RR: Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol 39: 629-640, 1996.
40. MacMahon B: Overview of studies on endometrial cancer and other types of cancer in humans. Perspectives of an epidemiologist. Sem Oncol 24 (suppl 1): S1-122-S1-139, 1997.
41. Daniel J, Jubar M, Bar-Am A, Peyser R, Lessing J. The effects of tamoxifen treatment on the endometrium. Fert Steril 65: 1083-1089, 1996.
42. Magriples V, Naftolin F, Schwartz PE and Carrangin ML: High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 11: 485-490, 1993.
43. Shepherd JH: Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96: 889-892, 1989.
44. Love RR: Tamoxifen prophylaxis in breast caner. Oncology (Williston Park) 6: 33-43, 1992.
45. Fentimen IS and Powles TJ: Tamoxifen and benign breast problems. Lancet ii: 1070-1077, 1987.
46. Powels TJ, Tillyer CR and Jones AJ: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme, Eur J Cancer 26: 680-684, 1990.
47. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R and Tancer ML: Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer. Preliminary report. Gynecol Oncol 42: 120-123, 1991.
48. Kedar RP, Bourne TH, Powles TJ: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343: 1318-1321, 1994.
49. Hacker NF: Uterine cancer. In: Practical Gynaecologic Oncology (Berek J and Hacker N eds.). Baltimore Williams and Wilkins, 1994, pp. 285-326.